[Present state of antimycotic therapy (author's transl)].
In the local treatment of various forms of dermatophytosis tolnaftate used to be the most convincing drug. More recent developments have led to a group of imidazol derivatives which have a broader spectrum and are also effective against yeasts. Polyene antibiotics are still very useful in the treatment of Candida mycoses. There are only few drugs available for systemic treatment of mycoses. Grisefulvin is only effective against dermatophytes. Amphotericin B, given intravenously, is a very useful drug against a series of systemic mycoses but it's value is decreased by serious side effects. Fluorocytosin shows less unwanted effects than Amphotericin B, but many fungi are resistent against this antimycotic or may become so during treatment. Of the imidazol group only miconazole is available for systemic intravenous therapy. Further developments of systemic antimycotics are of great importance.
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D002648:Child; D005437:Flucytosine / Q000627:therapeutic use; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008825:Miconazole / Q000627:therapeutic use; D011090:Polyenes / Q000627:therapeutic use; D014005:Tinea / Q000188:drug therapy; D014047:Tolnaftate / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D011090:Polyenes; D014047:Tolnaftate; D006118:Griseofulvin; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine
Gegenwärtiger Stand der antimykotischen Therapie.